SynthesisPloS one2026
Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis.
Synthesis in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plexiform neurofibromas arise in up to half of people with neurofibromatosis type 1 (NF1), causing pain, disfigurement and functional loss. Loss of neurofibromin releases RAS-MAPK signaling, making MEK1/2 a rational target. Two agents are now approved in the United States, the adult indication only since 2025. We evaluated the efficacy and safety of MEK inhibitor monotherapy in NF1-associated symptomatic, inoperable plexiform neurofibroma across children and adults. We searched six databases and registries from inception to 10 July 2026, reporting per PRISMA 2020. The primary outcome was objective response rate (≥20% tumor volume reduction, REiNS criteria). Two reviewers screened, extracted and appraised studies (RoB 2, ROBINS-I); certainty was rated with GRADE. Proportions were pooled using random-effects models after Freeman-Tukey transformation, with subgrouping by age. Eleven reports of nine studies (528 participants) met eligibility, covering selumetinib, mirdametinib, trametinib and binimetinib. The pooled descriptive response rate was 53.7% (95% CI 40.5-66.6; I2 = 84.0%) and varied by age: 62.9% in children versus 40.8% in adults. Because eight of the nine strata were single-arm, these are descriptive pooled proportions rather than controlled treatment effects. Adult heterogeneity was driven almost entirely by KOMET, the only randomized trial (20% versus 5% with placebo, p = 0.011); excluding it, the adult estimate was 49.0%. Responses were partial but usually durable, with improvements in pain and quality of life. Toxicity was mostly low grade, with uncommon cardiac and ocular events. MEK inhibition shrinks symptomatic inoperable plexiform neurofibromas in children and adults and is now supported by randomized evidence, although pooled estimates represent a weighted average across four pharmacologically distinct agents rather than a single class effect. Benefit is partial and depends on continued treatment. Optimal duration, comparative effectiveness and any effect on malignant transformation remain undefined.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.